Scientists Uncover a Hidden Brain Source Fueling Dementia: Free Radicals in Astrocytes
Scientists at Weill Cornell Medicine have made a groundbreaking discovery that could revolutionize our understanding of dementia. They've identified a surprising culprit: free radicals generated in a specific region of brain support cells called astrocytes. This finding, published in Nature Metabolism, suggests a new strategy for treating neurodegenerative diseases like frontotemporal dementia and Alzheimer's.
Dr. Anna Orr, a leading researcher, expresses excitement about the study's potential. "We can now target specific mechanisms and focus on the exact sites relevant to disease."
The research delves into the role of mitochondria, the cell's energy producers, and their release of reactive oxygen species (ROS), or free radicals. While normal levels of ROS help regulate cell functions, excessive or untimely production can cause damage.
Dr. Adam Orr explains, "Mitochondrial ROS have been linked to neurodegenerative diseases for decades."
Antioxidants have long been tested to neutralize ROS and slow neurodegeneration, but clinical trials have been unsuccessful. Dr. Adam Orr attributes this to antioxidants' inability to target ROS at their source without affecting cell metabolism.
To address this, Dr. Orr developed a drug discovery platform to find molecules that suppress ROS at individual mitochondrial sites. They identified S3QELs, compounds that showed promise in blocking harmful ROS activity.
The study's surprising finding: excess ROS didn't originate from neurons but from astrocytes, non-neuronal cells supporting neurons. Daniel Barnett, the lead author, noted, "Significant neuronal protection was observed only in the presence of astrocytes."
Further experiments revealed that astrocytes, when exposed to disease factors, increased mitochondrial ROS production. Treatment with S3QELs suppressed this rise, while targeting other ROS sources had no similar effect. Barnett discovered that ROS oxidized immune and metabolic proteins, altering gene activity linked to inflammation and dementia.
The team's animal experiments yielded promising results. Administering S3QELs to dementia-model mice reduced astrocyte activation, inflammatory gene expression, and a tau modification linked to dementia. Even when treatment started after symptoms appeared, it improved lifespan and had no significant side effects.
Dr. Anna Orr highlights the study's impact on free radical research, opening new avenues for investigating inflammation and neurodegeneration. The findings have the potential to reshape how scientists approach these complex diseases.
